Future Uncertain For Gamida Despite Omisirge Optimism

30 Jan 2024

Gamida Cell's Omisirge made it to the US market at the end of last year but despite a better-than-expected launch, the Israeli group has been forced to explore strategic alternatives to survive.

Gamida Cell Ltd.'s allogeneic cell therapy Omisirge has enjoyed a decent commercial launch following US approval last year but the Israeli biotech remains cash-strapped and is struggling to stay afloat.

The Kiryat Gat-based biotech, which has offices in Boston and is listed on the NASDAQ, got the green light from the US Food and Drug Administration in April 2023 for Omisirge (omidubicel), a treatment for patients with blood cancers awaiting stem cell transplant which is designed to reduce the time to neutrophil recovery and lower infection incidence

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

12 May 2025

• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.